Wilmington Savings Fund Society FSB Has $29.39 Million Stock Holdings in Eli Lilly and Company $LLY

Wilmington Savings Fund Society FSB decreased its holdings in shares of Eli Lilly and Company (NYSE:LLY) by 4.5% during the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 37,704 shares of the company’s stock after selling 1,786 shares during the period. Wilmington Savings Fund Society FSB’s holdings in Eli Lilly and Company were worth $29,391,000 as of its most recent SEC filing.

Several other institutional investors have also recently bought and sold shares of the business. Founders Grove Wealth Partners LLC raised its holdings in Eli Lilly and Company by 0.3% during the second quarter. Founders Grove Wealth Partners LLC now owns 21,460 shares of the company’s stock worth $16,729,000 after buying an additional 61 shares during the last quarter. Sage Advisors LLC raised its holdings in Eli Lilly and Company by 1.4% during the second quarter. Sage Advisors LLC now owns 18,974 shares of the company’s stock worth $14,791,000 after buying an additional 270 shares during the last quarter. Axxcess Wealth Management LLC raised its holdings in Eli Lilly and Company by 1.2% during the second quarter. Axxcess Wealth Management LLC now owns 20,735 shares of the company’s stock worth $16,163,000 after buying an additional 238 shares during the last quarter. Moran Wealth Management LLC raised its holdings in Eli Lilly and Company by 4.0% during the second quarter. Moran Wealth Management LLC now owns 9,829 shares of the company’s stock worth $7,662,000 after buying an additional 376 shares during the last quarter. Finally, Elefante Mark B raised its holdings in Eli Lilly and Company by 124.0% during the second quarter. Elefante Mark B now owns 1,317 shares of the company’s stock worth $1,027,000 after buying an additional 729 shares during the last quarter. Institutional investors and hedge funds own 82.53% of the company’s stock.

Insider Transactions at Eli Lilly and Company

In other Eli Lilly and Company news, CEO David A. Ricks purchased 1,632 shares of Eli Lilly and Company stock in a transaction on Tuesday, August 12th. The shares were acquired at an average cost of $644.77 per share, for a total transaction of $1,052,264.64. Following the completion of the transaction, the chief executive officer directly owned 546,601 shares of the company’s stock, valued at approximately $352,431,926.77. The trade was a 0.30% increase in their ownership of the stock. The purchase was disclosed in a filing with the SEC, which is available through this hyperlink. Also, Director J Erik Fyrwald bought 1,565 shares of the business’s stock in a transaction dated Tuesday, August 12th. The stock was purchased at an average price of $642.33 per share, for a total transaction of $1,005,246.45. Following the acquisition, the director directly owned 74,578 shares of the company’s stock, valued at approximately $47,903,686.74. The trade was a 2.14% increase in their position. The disclosure for this purchase can be found here. In the last 90 days, insiders bought 4,514 shares of company stock valued at $2,894,841. Company insiders own 0.14% of the company’s stock.

Analyst Ratings Changes

Several research analysts have weighed in on the stock. Cantor Fitzgerald set a $925.00 price objective on shares of Eli Lilly and Company and gave the stock an “overweight” rating in a report on Thursday. The Goldman Sachs Group upped their target price on shares of Eli Lilly and Company from $876.00 to $879.00 and gave the stock a “buy” rating in a research note on Friday. Leerink Partners reiterated a “market perform” rating and issued a $715.00 target price on shares of Eli Lilly and Company in a research note on Thursday, August 7th. Berenberg Bank reiterated a “hold” rating and issued a $830.00 target price (down previously from $970.00) on shares of Eli Lilly and Company in a research note on Wednesday, September 17th. Finally, Daiwa Capital Markets lowered shares of Eli Lilly and Company from an “outperform” rating to a “neutral” rating and set a $700.00 target price for the company. in a research note on Sunday, August 17th. One research analyst has rated the stock with a Strong Buy rating, fourteen have given a Buy rating and ten have issued a Hold rating to the company. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $948.06.

Eli Lilly and Company Price Performance

LLY opened at $818.60 on Tuesday. Eli Lilly and Company has a fifty-two week low of $623.78 and a fifty-two week high of $937.00. The firm has a market cap of $774.77 billion, a P/E ratio of 53.50, a PEG ratio of 1.18 and a beta of 0.47. The company has a debt-to-equity ratio of 1.86, a quick ratio of 1.00 and a current ratio of 1.28. The firm has a 50-day moving average of $743.43 and a 200 day moving average of $765.54.

Eli Lilly and Company (NYSE:LLY) last announced its quarterly earnings results on Thursday, August 7th. The company reported $6.31 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $5.59 by $0.72. Eli Lilly and Company had a net margin of 25.91% and a return on equity of 92.72%. The firm had revenue of $15.56 billion for the quarter, compared to the consensus estimate of $14.40 billion. During the same period in the prior year, the firm posted $3.92 earnings per share. The company’s revenue for the quarter was up 37.6% on a year-over-year basis. Eli Lilly and Company has set its FY 2025 guidance at 21.750-23.000 EPS. On average, research analysts expect that Eli Lilly and Company will post 23.48 EPS for the current year.

About Eli Lilly and Company

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.